Medscape October 23, 2024
Amina Niasse

NEW YORK (Reuters) – Most U.S. states do not currently cover highly sought after weight-loss drugs from Novo Nordisk and Eli Lilly in their Medicaid health programs for low income people, citing cost as a key factor, according to a survey conducted by health research firm KFF.

The survey of the 50 states and the District of Columbia found that just 12 Medicaid programs covered the drugs to treat obesity as of July 2024 with some limits on use.

Half of the states without coverage said they are considering adding them or evaluating their coverage, it said.

The drugs from a class known as GLP-1 agonists were initially developed to treat type 2 diabetes but also promote weight loss by...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Insurance, Medicaid, Survey / Study, Trends
Related Articles:
Resumption Of Medicaid Eligibility Redeterminations: Little Change In Overall Insurance Coverage
After Pandemic-Era Policies and Enhanced Funding End, State Medicaid Officials Report Enrollment Declines and Upward Cost Pressures
Medicaid Enrollment & Spending Growth: FY 2024 & 2025
As Pandemic-Era Policies End, Medicaid Programs Focus on Enrollee Access and Reducing Health Disparities Amid Future Uncertainties: Results from an Annual Medicaid Budget Survey for State Fiscal Years 2024 and 2025
More state Medicaid programs consider covering GLP-1 drugs

Share This Article